SAN DIEGO, CA--(Marketwire - October 29, 2008) - Lpath, Inc. (OTCBB: LPTN) and Merck Serono, a division of Merck KGaA, Darmstadt, Germany, have entered into a worldwide alliance to develop and commercialize ASONEP, Lpath's Phase 1 monoclonal antibody that is being evaluated for the treatment of cancer.
